[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100357388":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":37,"locations":46,"responsibleParty":61,"collaborators":50,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":50,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":50,"enrollmentInfo":74,"targetDuration":50,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":48,"whyStopped":50,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Taichung Veterans General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tenofovir alafenamide group","ACTIVE_COMPARATOR","Study subjects will receive tenofovir alafenamide 25 mg\u002Ftab once daily",[13],"Drug: Tenofovir alafenamide",{"label":15,"type":10,"description":16,"interventionNames":17},"Entecavir group","Study subjects will receive entecavir 0.5 mg\u002Ftab once daily",[18],"Drug: Entecavir",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Tenofovir alafenamide","Tenofovir alafenamide 25mg\u002Ftab once daily",[9],[26],"Vemlidy",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Entecavir","Entecavir 0.5mg\u002Ftab once daily",[15],[32],"Baraclude",[34],{"name":35,"affiliation":5,"role":36},"Teng-Yu Lee, MD, PhD","STUDY_CHAIR",[38,43],{"name":35,"role":39,"phone":40,"phoneExt":41,"email":42},"CONTACT","886-4-23592525","3301","tylee@vghtc.gov.tw",{"name":44,"role":39,"phone":40,"phoneExt":41,"email":45},"Hsin-Ju Tsai, MD","a9194024@hotmail.com",[47],{"facility":5,"status":48,"city":49,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Taichung",null,"Taiwan","TW",{"type":54,"coordinates":55},"Point",[56,57],120.6839,24.1469,{"lat":57,"lon":56},[60],{"name":35,"role":39,"phone":40,"phoneExt":41,"email":42},{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":50,"oldOrganization":50},"PRINCIPAL_INVESTIGATOR","Teng-Yu Lee","Principal Investigator","100357388","phase-4-tenofovir-alafenamide-versus-entecavir-for-the-treatment-of-chronic-hepatitis-b-100357388",false,"NCT03933384","Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B","Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients more than 20 years old\n2. Chronic hepatitis B patients\n3. Patients who were indicated for hepatitis B virus antiviral therapy\n\nExclusion Criteria:\n\n1. Decompensated liver disease (Child-Pugh B \\&C)\n2. End stage renal disease (eGRF \\\u003C 15 ml\u002Fmin\u002F1.73m2)\n3. Prior use of nucleot(s)ide analogues for chronic hepatitis B\n4. Prior use of interferon for chronic hepatitis B within six months\n5. Known history of human immunodeficiency virus or hepatitis C virus co-infection\n6. Concurrent other uncontrolled malignancy\n7. Women in pregnancy or lactation\n8. Cannot conform to the study protocol of this study","ALL","20 Years",{"count":75,"type":76},140,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.",[82,83],"Hepatitis B","Viral Hepatitis",[82,83,22,28],"2026-05-11",{"date":87,"type":88},"2026-05-14","ACTUAL",{"date":90,"type":88},"2019-08-19",{"date":92,"type":76},"2030-12-31",{"name":5,"class":6},1]